Showing 3801-3810 of 4063 results for "".
- Limelight Bio Emerges with $75 Million to Develop Next Generation Gene Therapieshttps://modernod.com/news/limelight-bio-emerges-with-75-million-to-develop-next-generation-gene-therapies/2477141/Limelight Bio, a privately held, multi-platform, multi-disease biopharmaceutical company developing novel gene therapies, raised $75 million in new financing funded by Apple Tree Partners (ATP), a life sciences innovation fund. Founded in 2017, Limelight Bio has developed proprietary technologies
- Study Shows Superior Success Rate for ExTra ELT Compared With Trabectome in Patients With Glaucoma Plus Cataract Surgeryhttps://modernod.com/news/study-shows-superior-success-rate-for-extra-elt-compared-with-trabectome-in-patients-with-glaucoma-plus-cataract-surgery/2477135/ELT Sight announced that in the largest published study to date on excimer laser trabeculostomy (ELT), the ExTra ELT procedure plus cataract surgery was superior to ab interno trabeculectomy with the Trabectome plus cataract surgery, according to a company news release. The 245-patient
- Clearwave Announces Interface with Modernizing Medicinehttps://modernod.com/news/clearwave-announces-interface-with-modernizing-medicine/2477113/Clearwave, a provider of patient check-in solutions via mobile, kiosk and desktop, announced a new interface with award-winning health IT company, Modernizing Medicine. This announcement comes as Modernizing Medicine’s 2019 user conference, MOMENTUM, kicks off in Orlando, Florida. The Clea
- Aerie Pharmaceuticals Announces Agreement to Acquire Avizorex Pharma to Advance Its Dry Eye Programhttps://modernod.com/news/aerie-pharmaceuticals-announces-agreement-to-acquire-avizorex-pharma-to-advance-its-dry-eye-program/2477097/Aerie Pharmaceuticals announced it is acquiring Avizorex Pharma, a Spanish ophthalmic pharmaceutical company developing therapeutics for the treatment of dry eye disease. AVX completed a phase 2a study in dry eye subjects earlier this year with its lead product candidate, AVX-012. The acti
- Understanding the Eye’s ‘Plumbing’ Could Lead to Future Treatments for Glaucoma, Other Diseaseshttps://modernod.com/news/understanding-the-eyes-plumbing-could-lead-to-future-treatments-for-glaucoma-other-diseases/2477092/Scientists in the University of Arizona Department of Physiology have identified a potential molecular mechanism that may hold the key to understanding how pressure is regulated in the eye. Funded by a $2.3 million 5-year grant from the National Institutes of Health (NIH) National Eye Inst
- Vision Plan Customer Satisfaction Increases, J.D. Power Findshttps://modernod.com/news/vision-plan-customer-satisfaction-increases-j-d-power-finds/2477073/Overall customer satisfaction among vision plan members has increased in 2019, driven by improved perceptions of value and coverage. According to the J.D. Power 2019 Vision Plan Satisfaction Report, overall satisfaction increased by 17 points (on a 1,000-point scale) to 770 this year from 753 in
- Oyster Point Pharma Announces Pricing of Initial Public Offeringhttps://modernod.com/news/oyster-point-pharma-announces-pricing-of-initial-public-offering/2477064/Oyster Point Pharma announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a price to the public of $16.00 per share. The shares began trading on The Nasdaq Global Select Market on October 31, 2019 under the symbol “OYST.” All of the shares ar
- Iveric bio Appoints Abraham Scaria, PhD, as Chief Scientific Officerhttps://modernod.com/news/iveric-bio-appoints-abraham-scaria-phd-as-chief-scientific-officer/2477050/Iveric bio announced the appointment of Abraham Scaria, PhD, to the position of Chief Scientific Officer, effective October 29, 2019. Dr. Scaria will lead the company’s research and preclinical gene therapy activities. Dr. Scaria’s extensive experience includes positions at Genzyme, Sanofi, and m
- CooperVision’s ECP Viewpoints Begins Educational Series Based on Company and Company-Sponsored Researchhttps://modernod.com/news/coopervisions-ecp-viewpoints-begins-educational-series-based-on-company-and-company-sponsored-research/2477042/Eye care professionals attending Academy 2019 have access to hundreds of scientific papers and posters that showcase the latest advances in optometry research. But digesting and translating this information for the benefit of their own practices can be a challenge. To further support its clinical
- SightGlass Vision to Present New Data on its Novel Lenses to Control Nearsightedness in Children at 3rd World Congress of Optometryhttps://modernod.com/news/sightglass-vision-to-present-new-data-on-its-novel-lenses-to-control-nearsightedness-in-children-at-3rd-world-congress-of-optometry/2477040/SightGlass Vision announced that data from three clinical trials overviewing discovery to clinical development of its novel spectacle lenses will be presented for the first time in a scientific forum at the 3rd World Congress of Optometry (WCO19) and Academy 2019 (Academy19), held